Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease

Drug Development Research

Volumn 38, Issue 3-4, 1996, Pages 278-289

  Newhouse, Paul ^a,c   Potter, Alexandra ^a   Corwin, June ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Alzheimer's disease; Attention; Mecamylamine; Memory; Nicotine; Parkinson's disease

Indexed keywords

MECAMYLAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BRAIN DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; MEMORY; MEMORY CONSOLIDATION; NORMAL HUMAN; PARKINSON DISEASE; VISION;

EID: 0030459333     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199607/08)38:3/4<278::AID-DDR17>3.0.CO;2-V     Document Type: Article

References (108)

1. Arnerić SP (1989): Basal forebrain neurons modulate cortical cerebral blood flow: Increases by nicotinic cholinergic mechanisms. J Cereb Blood Flow Metab 9(suppl 1):S502.
2. Arnerić SP, Sullivan JP, Williams M (1995): Neuronal nicotinic receptors: Novel targets for central nervous system therapeutics. In Bloom F, Kupfer D (eds): Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp 95-110.
3. Aubert I, Araujo DM, Cécyre D, Robitaille Y, Gauthier S, Quirion R (1992): Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58:529-541.
4. 3H]methylcarbamylcholine binding sites and the effect of N-methylcarbamylcholine on acetylcholine release in rat brain. J Neurochem 51:292-299.
5. Baddeley A (1986): Working Memory, Oxford: Clarenden Press.
6. Baddeley AD, Bressi S, Sala SD, Logie R, Spinnler H (1991): The decline of working memory in Alzheimer's disease. Brain 114: 2521-2542.
7. Baddeley A, Logie R, Bressi S, Della Sala S, Spinnler H (1986): Dementia and working memory. J Exp Psychol 38A:603-618.
8. Baron JA (1986): Cigarette smoking and Parkinson's disease. Neurology 36:1490-1496.
9. Baron JA (1994): Epidemiology of smoking and Parkinson's disease, In Clarke PBS, Quik M, Thurau K, Adlkofer F (eds): Boston: Birkhäuser, S42.
10. Baumann RJ, Jameson HD Effects of Nicotine on Biological Systems. II. McKean HD, Haack DG, Weisberg LM (1980): Cigarette smoking and Parkinson's disease. 1. Comparison of cases with matched neighbors. Neurology 30:839-843.
11. Baumann RJ, Jameson HD Effects of Nicotine on Biological Systems. II. McKean HD, Haack DG, Weisberg LM (1980): Cigarette smoking and Parkinson's disease. 1. Comparison of cases with matched neighbors. Neurology 30:839-843.
12. Bartus R, Dean R, Beer B, Lippa A (1982): The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
13. Beatty WW, Butters N, Janowsky D (1986): Patterns of memory failure after scopolamine treatment: Implications for the cholinergic hypothesis of dementia. Behav Neur Biol 45:196-211.
14. Brazzelli M, Cocchini G, Delia Sala S, Spinnler H (1994): Alzheimer patients show a sensitivity decrement over time on a tonic alertness task. J Clin Exp Neuropsychol 16:851-860.
15. Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN (1986): Muscarinic agonist therapy of Alzheimer's disease. Arch Neurol 43: 659-661.
16. Brown RG, Marsden CD (1990): Cognitive function in Parkinson's disease: From description to theory. Trends Neurosci 13:21-29.
17. Brown RG, Marsden CD (1991): Dual task performance and processing resources in normal subjects and patients with Parkinson's disease. Brain 114:215-231.
18. Callaway E, Halliday R, Naylor H, Schector G (1985): Effects of oral scopolamine on human stimulus evaluation. Psychopharmacology 85:133-138.
19. Cordell B (1994): β-amyloid formation as a potential therapeutic target for Alzheimer's disease. Annu Rev Pharmacol Toxicol 34:69-89.
20. Corkin, S (1981): Acetylcholine, aging, and Alzheimer's disease: implications of treatment. Trends Neurosci 4:287-290.
21. Cossa FM. Delia Sala S, Spinnler H (1989): Selective visual attention in Alzheimer's and Parkinson's patients: Memory- and data-driven control. Neuropsychologia 27:887-892.
22. Dalrymple-Alford JC, Raiders AS, Jones RD, Watson RW (1994): A central executive deficit in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57:360-367.
23. De Sarno P, Giacobini E (1989): Modulation of acetylcholine release by nicotinic receptors in the rat brain. J Neurosci Res 22:194-200.
24. Delong MR, Georgopoulos AP, Crutcher MD (1983): Corticobasal ganglia relations and coding of motor performance. Exp Brain Res 49(suppl 7):30-40.
25. Doucette-Stamm L, Monteggia L, Donnelly-Roberts D, Wang WT, Tian JL, Giordano T (1993): Cloning and sequence of the human α7 nicotinic acetylcholine receptor. Drug Dev Res 30: 252-256.
26. Downes JJ, Sharp HM, Sagar HJ (1991): The time course of negative priming in Parkinson's disease. J Clin Exp Neuropsych 13:75
27. Downes JJ, Sharp HM, Costall BM, Sagar HJ, Howe J (1993): Alternating fluency in Parkinson's disease. An evaluation of the attentional control theory of cognitive impairment. Brain 116: 887-902.
28. Drachman D, Leavitt J (1974): Human memory and the cholinergic system. Arch Neurol 30:113-121.
29. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987): Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 22:26-30.
30. Dubois B, Pillon R, Lhermitte F, Agid Y (1990): Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 28:117-121.
31. Dunne MP, Hartley LR (1985): The effects of scopolamine upon verbal memory: Evidence for an attentional hypothesis. Acta Psychol 58:205-217.
32. 3H]nicotine binding in human cerebral cortex: Comparison between Alzheimer's disease and the normal. J Neurochem 47:1948-1954.
33. Fuld P, Katzman R, Davies P, Terry RD (1982): Intrusions as a sign of Alzheimer dementia: Chemical and pathological verification. Ann Neurol 11:155-159.
34. Giacobini E (1990): Cholinergic receptors in human brain: Effects of aging and Alzheimer's disease. J Neurosci Res 27:548-560.
35. Gitelman DR, Prohovnik I (1992): Muscarinic and nicotinic contributions to cognitive function and cortical blood flow. Neurobiol Aging 13:313-318.
36. Goldenberg G, Lang W, Podreka I, Deecke L (1990): Are cognitive deficits in Parkinson's disease caused by frontal lobe dysfunction? J Psychophysiol 4:137-144.
37. Hassler R (1978): Srriatal control of locomotion, intentional actions and of integrating and perceptive activity. J Neurol Sci 36:187-224.
38. Heishman SJ, Taylor RC, Henningfield JE (1994): Nicotine and smoking: A review of effects on human performance. Exp Clin Psychopharmacol 2:345-395.
39. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992): Effects of acute subcutaneous nicotine on attention, information processing and short term memory in Alzheimer's disease. Psychopharmacology 108:485-494,
40. Katayama S, Hirata K, Tanaka H, Yamazaki K, Fujikane M, Ichimaru Y (1995): Efficacy of transdermal nicotine in dementia: A study using event-related potentials and a middle latency response. In Domino EF (ed): Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor, MI: NPP Books, pp 289-302.
41. Le Houezec J, Halliday R, Benowitz NL, Callaway E, Naylor H, Herzig K (1994): A low dose of nicotine improves information processing in non-smokers. Psychophamacology 114:628-634.
42. Lee PN (1994): Smoking and Alzheimer's disease: A review of the epidemiologic evidence. Neuroepidemiology 13:131-144.
43. Lena C, Changeux JP (1993): Allosteric modulations of the nicotinic acetylcholine receptor. TINS 16:181-186.
44. Levin E (1992): Nicotinic systems and cognitive function. Psychopharmacology 108:417-431.
45. Levin E, McGurk SR, Rose JE, Butcher LL (1990): Cholinergic-dopaminergic interactions in cognitive performance. Behav Neural Biol 54:271-299.
46. Linville DC, Arnerić SP (1991): Cortical cerebral blood flow governed by the basal forebrain: Age related impairments. Neurobiol Aging 12:503-510.
47. Linville DC, Williams S, Arnerić SP (1993): Basal forebrain control of cortical cerebral blood flow is independent of local cortical neurons. Brain Res 622:26-34.
48. London E, Fanelli RJ, Kimes A, Mosers R (1990): Effects of chronic nicotine on cerebral glucose utilization in the rat. Brain Res 520:208-214.
49. Marrocco RT, White EA (1993): Soc Neurosci Abs 19:561.
50. McCormick DA (1990): Cellular mechanism of cholinergic control of neocortical and thalamic neuronal excitability. In Steriade M, Biesold D (eds): Brain Cholinergic Systems. New York: Oxford University Press, pp 236-264.
51. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW (1995): Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269:1692-1696.
52. Moll H (1926): The treatment of postencephalitic parkinsonism by nicotine. BMJ 1:1079-1081.
53. Myrsten A, Post B, Frankenhaeuser M, Johansson G (1972): Changes in behavioral and physiological activation induced by cigarette smoking in habitual smokers. Psychopharmacology (Berl) 76:232-235.
54. Newhouse PA (1990): Cholinergic drug studies in dementia and depression. Adv Exp Med Biol 282:65-76.
55. Newhouse PA, Belenky GL, Thomas MA (1989): The effects of d-amphetamine on arousal, cognition, and mood after prolonged sleep deprivation. Neuropsychopharmacology 2:153-164.
56. Newhouse PA, Penetar D, Fertig J (1992): Stimulant drug effects after prolonged total sleep deprivation: A comparison of amphetamine, nicotine, and deprenyl. Mil Psychol 4:207-234.
57. Newhouse PA, Potter A, Corwin J, Lenox R (1992): Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology 108:480-484.
58. Newhouse PA, Potter A, Lenox RH (1993): Effects of nicotinic agents on human cognition: Possible therapeutic applications in Alzheimer's and Parkinson's diseases. Med Chem Res 2:628-642.
59. Newhouse PA, Potter A, Corwin J, Lenox RH (1994): Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10:93-107, 1994.
60. Newhouse PA, Potter A, Corwin J, Lenox RH (1995): Acute cognitive effects of nicotine in Alzheimer's and Parkinson's disease. Presented at the Thirty-fourth Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, Dec 11-15, 1995.
61. Newhouse PA, Sunderland T, Tariot PN (1988a): The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry 45:906-912.
62. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL (1988b): Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology 95:171-175.
63. Newhouse PA, Sunderland T, Narang PK, Mellow AM, Fertig JB, Lawlor BA, Murphy DL (1990): Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease. Psychoneuroendocrinology 15:471-484.
64. Nordberg A (1994): Human nicotinic receptors - their role in aging and dementia. Neurochem Int 25:93-97.
65. Oken BS, Kishiyama SS, Kaye JA, Howieson DB (1994): Attention deficit in Alzheimer's disease is not stimulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging. Neurology 44:657-662.
66. Oliverio A (1966): Effects of mecamylamine on avoidance conditioning and maze learning of mice. J Pharmacol Exp Ther 154: 350-356.
67. Parasuraman R, Haxby JV (1993): Attention and brain function in Alzheimer's disease. Neuropsychology 7:242-272.
68. Parasuraman R, Greenwood PM, Haxby JV, Grady CL (1992): Visuospatial attention in dementia of the Alzheimer type. Brain 115:711-733.
69. Parasuraman R, Martin A (1994): Cognition in Alzheimer's disease: Disorders of attention and semantic knowledge. Curr Opin Neurobiol 4:237-244.
70. Parks RW, Young CS, Rippey RF, Becker RE (1994): Nicotinic stimulation of anterior regional glucose metabolism in Alzheimer's disease: Preliminary study with transdermal patches. In Giacobini E, Becker R (eds): Alzheimer's Disease: Therapeutic Strategies. Boston: Birkhäuser, pp 424-427.
71. Parrott AC, Craig D (1992): Cigarette smoking and nicotine gum (0, 2 and 4 mg): Effects upon four visual attention tasks. Neuropsychobiology 25:34-43.
72. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR (1985): Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48:413-421.
73. Peterson R (1977): Scopolamine-induced learning failures in man. Psychopharmacology 52:283-289.
74. Posner MI (1980): Orienting of attention. Q J Exp Psychol 32:3-25.
75. Prohovnik I, Mayeux R, Sackheim HA, Smith G, Stern Y, Alderson PO (1988): Cerebral profusion as a diagnostic marker of early Alzheimer's disease. Neurology 38:931-937.
76. Provost SC, Woodward R (1991): Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology 104:536-540.
77. Quirion R, Richard J, Wilson A (1994): Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving rats. Synapse 17:92-100.
78. Reading PJ (1991): Frontal lobe dysfunction in schizophrenia and Parkinson's disease - a meeting point for neurology, psychology and psychiatry: Discussion paper. J R Soc Med 84:349-353.
79. Reid WGJ, Broe GA, Morris JGL, Hely MA, Moss NG, Genge SA, O'Sullivan DJ, Williamson PM (1990): The role of cholinergic deficiency in neuropsychological deficits in idiopathic Parkinson's disease. Dementia 3:114-120.
80. Bobbins TW, Brown VJ (1990): The role of the striatum in the mental chronometry of action: A theoretical review. Rev Neurosci 2:181-213.
81. 3H]acetylcholine release from mouse cerebral cortical synaptosomes. J Neurochem 43:1593-1598.
82. Ruberg M, Ploska F, Javoy-Agid F, Agid Y (1982): Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res 232:129-139.
83. Rusted J, Graupner L, O'Connell N, Nicholls C (1994): Does nicotine improve cognitive function? Psychopharmacology 115: 547-549.
84. Sahakian BJ, Coull JT (1994); Nicotine and THA: Evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 31:80-88.
85. 3H]acetylcholine on catecholamine and serotonin receptors in brain. J Neurochem 42:1495-1498.
86. Sershen H, Hashim, A, Lajtha A (1987): Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease. Pharmacol Biochem Behav 28:299-303.
87. Sitaram N, Weingartner H, Gillin J (1978): Human serial learning: enhancement with arecholine and choline and impairment with scopolamine. Science 201:274-276.
88. Snodgrass J, Corwin J (1988): Pragmatics of recognition memory: Application to dementia and amnesia. J Exp Psychol (Gen) 117: 34-50.
89. Snyder FR, Henningfield JE (1989): Effects of nicotine administration following 12 hours of tobacco deprivation: Assessment on computerized performance tasks. Psychopharmacology 97:17-22.
90. Spillich GJ, June L, Renner J (1992): Cigarette smoking and cognitive performance. Br J Addiction 87:1313-1326.
91. Stam CJ, Visser SL, Op de Coul AAW, De Sonneville LMJ, Schellens HLLA, Brunia CHM, de Smet JS, Gielen G (1993): Disturbed frontal regulation of attention in Parkinson's disease. Brain 116:1139-1158.
92. Stuss DT, Benson DF (1986): The Frontal Lobes. New York: Raven Press.
93. Sunderland T, Tariot, P, Weingartner H, Newhouse P, Cohen RM (1986): Pharmacologic modelling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10:599-610.
94. Tariot P, Cohen R, Welkowitz J, Sunderland T, Newhouse PA, Mueller EA, Cohen RM (1988): Multiple dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 45:901-905.
95. Tarroni P, Rubboli F, Chini B, Clementi F (1992): Neuronal-type nicotinic receptors in human neuroblastoma and small-cell lung carcinoma cell lines. FEBS Lett 312:66-70.
96. Taylor AE, Saint-Cyr JA, Lang AE (1986): Frontal lobe dysfunction in Parkinson's disease: The cortical focus of neostriatal outflow. Brain 109:845-883.
97. Warburton DM, Rusted JM (1993): Cholinergic control of cognitive resources. Neuropsychobiology 28:43-46.
98. Wesnes K, Revell A (1984). The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 84:5-11.
99. Wesnes K, Warburton D (1983): Smoking, nicotine, and human performance. Pharmacol Ther 21:189-208.
100. Wesnes K, Warburton D (1985): Effects of scopolamine and nicotine on human performance. Psychopharmacology 82:147-150.
101. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, De Long MR (1982): Alzheimer's disease and senile dementia - loss of neurons in the basal forebrain. Science 215:1237-1239.
102. Whitehouse PJ, Hedreen JC, White CL, Price DL (1983): Basal forebrain neurons in dementia of Parkinson's disease. Ann Neural 13:243-248.
103. Whitehouse P, Martino A, Antuono P, Kellar K (1986): Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 371:146-151.
104. Whitehouse PJ, Martino AM, Marcus KA, Zweig H, Singer H, Price D, Kellar K (1988): Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 45: 722-724.
105. Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR (1995): Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 51:509-514.
106. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG (1990): Preynaptic modulation of transmitter release by nicotinic receptors. In Nordberg A, Fuxe K, Holmstedt B, Sundwall A (eds): Progress in Brain Research. Amsterdam: Elsevier, pp 157-163.
107. Wozniak DF, Stewart GR, Finger S, Olney JW (1989): Comparison of behavioral effects of nucleus basalis magnocellularis lesions and somatosensory cortex ablation in the rat. Neuroscience 32:685-700.
108. Wright MJ, Burns RJ, Geffen GM, Geffen LB (1990): Covert orienting of visual attention in Parkinson's disease: An impairment in the maintenance of attention. Neuropsychologia 28:151-159.